Serum fibrosis markers (Procollagen-III-peptide, hyaluronic acid, transforming growth factor β-1), aspartate-aminotransferase to platelet ratio index (APRI), and transient elastography (FibroScan) in patients with chronic HCV infection

Abstract Background: Although liver biopsy (LB) is the gold standard for the morphological diagnosis of diseases of the liver, recent noninvasive tests may also help in the evaluation of liver fibrosis. We have studied blood fibrosis markers and liver stiffness (LS) measurement to assess fibrosis in different forms of chronic hepatitis C virus (HCV) infection. Patients and methods: Out of 119 HCV-infected patients, 75 had biopsy-proven chronic hepatitis C, 24 had HCV cirrhosis, 20 individuals were symptom-free HCV carriers with persistently normal alanine aminotransferase (PNA), and 30 healthy blood donors served as controls. Wai's aspartate-aminotransferase (AST) to platelet ratio index (APRI) was calculated from serum AST and blood platelet number. Serum HCV-RNA (hepatitis C virus ribonucleic acid), procollagen-III-peptide (P-III-P) and hyaluronic acid (HA), plasma transforming growth factor β-1 (TGFβ-1), Knodell's histological activity index (HAI), and METAVIR fibrosis score were determined, and for LS...

[1]  M. Janíčko,et al.  Circulating markers of liver fibrosis progression. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[2]  A. Canbay,et al.  NASH: Eine unterschätzte metabolische Komplikation der morbiden Adipositas , 2010 .

[3]  Long R. Jiao,et al.  A Meta-analysis of Transient Elastography for the Detection of Hepatic Fibrosis , 2010, Journal of clinical gastroenterology.

[4]  V. de Lédinghen,et al.  Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. , 2010, Journal of hepatology.

[5]  V. de Lédinghen,et al.  The combination of a blood test and Fibroscan improves the non‐invasive diagnosis of liver fibrosis , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[6]  J. Marín-Gabriel,et al.  Noninvasive assessment of liver fibrosis. Serum markers and transient elastography (FibroScan). , 2009, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[7]  M. Friedrich-Rust,et al.  Reproducibility and limitations of transient elastography , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[8]  Sheng-Nan Lu,et al.  FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis , 2009, Journal of Gastroenterology.

[9]  S. Varnous,et al.  Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency , 2008, Hepatology.

[10]  Gunda Millonig,et al.  Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis , 2008, Hepatology.

[11]  G. Tarantino,et al.  Can Serum TGF-BETA 1 Be Used to Evaluate the Response to Antiviral Therapy of Haemophilic Patients with HCV-Related Chronic Hepatitis ? , 2008, International journal of immunopathology and pharmacology.

[12]  A. Alberti,et al.  Implementing non-invasive markers for liver fibrosis in clinical practice. , 2008, Journal of hepatology.

[13]  Laurent Castera,et al.  Non-invasive evaluation of liver fibrosis using transient elastography. , 2008, Journal of hepatology.

[14]  Eva Herrmann,et al.  Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. , 2008, Gastroenterology.

[15]  Dieter Häussinger,et al.  Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage , 2007, Hepatology.

[16]  Massimo Pinzani,et al.  Acute viral hepatitis increases liver stiffness values measured by transient elastography , 2007, Hepatology.

[17]  Patrice Faure,et al.  Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. , 2007, Journal of hepatology.

[18]  Giacomo Belli,et al.  Liver stiffness measurement predicts severe portal hypertension in patients with HCV‐related cirrhosis , 2007, Hepatology.

[19]  A. Pár,et al.  A cirrhosis prevenciója - A májfibrosis diagnosztikája és a kezelés lehetoségei , 2006 .

[20]  Mario Plebani,et al.  Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. , 2006, Journal of hepatology.

[21]  B. Hunyady,et al.  599 Peg-IFN plus ribavirin therapy suppresses plasma TGF-β1, hyaluronic acid and procollagen-III-peptide levels in patients with chronic hepatitis C independently of virological response , 2006 .

[22]  D. Rockey,et al.  Noninvasive measures of liver fibrosis , 2006, Hepatology.

[23]  V. de Lédinghen,et al.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.

[24]  Christos Christidis,et al.  Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C , 2005, Hepatology.

[25]  N. Afdhal,et al.  Evaluation of Liver Fibrosis: A Concise Review , 2004, American Journal of Gastroenterology.

[26]  M. Ziol,et al.  Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. , 2003, Ultrasound in medicine & biology.

[27]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[28]  D. Schuppan,et al.  Hepatitis C and liver fibrosis , 2003, Cell Death and Differentiation.

[29]  J. McHutchison,et al.  Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C , 2003, Journal of gastroenterology and hepatology.

[30]  Llorenç Quintó,et al.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model , 2002, Hepatology.

[31]  S. Dooley,et al.  Roles of TGF-beta in hepatic fibrosis. , 2002, Frontiers in bioscience : a journal and virtual library.

[32]  P. Schirmacher,et al.  Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor‐β , 2001, Journal of viral hepatitis.

[33]  L. Adinolfi,et al.  Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis , 2001, British journal of haematology.

[34]  I. Kovalszky,et al.  Expression of decorin, transforming growth factor-beta 1, tissue inhibitor metalloproteinase 1 and 2, and type IV collagenases in chronic hepatitis. , 2001, American journal of clinical pathology.

[35]  T. Poynard,et al.  Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study , 2001, The Lancet.

[36]  R. Testa,et al.  Serum pro-collagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C , 2001, European journal of gastroenterology & hepatology.

[37]  O. Chazouilleres,et al.  Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. , 2000, Journal of hepatology.

[38]  R. Ohno,et al.  Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis , 1999, American Journal of Gastroenterology.

[39]  G. Davis,et al.  Transforming growth factor‐ß1 in chronic hepatitis C , 1997 .

[40]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[41]  M. Manns,et al.  Serum hyaluronate and type III procollagen aminoterminal propeptide concentration in chronic liver disease. Relationship to cirrhosis and disease activity , 1991, European journal of clinical investigation.

[42]  J. Hoofnagle,et al.  Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. , 1988, Gastroenterology.

[43]  R. Timpl,et al.  Radioimmunoassay for type III procollagen peptide and its application to human liver disease , 1979, European journal of clinical investigation.

[44]  E. Strauss,et al.  Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C. , 2009, Annals of hepatology.

[45]  Fabrice Carrat,et al.  Liver biopsy: the best, not the gold standard. , 2009, Journal of hepatology.

[46]  V. de Lédinghen,et al.  Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. , 2009, Journal of hepatology.

[47]  J. McHutchison,et al.  American Gastroenterological Association technical review on the management of hepatitis C. , 2006, Gastroenterology.

[48]  S. Friedman,et al.  Liver fibrosis -- from bench to bedside. , 2003, Journal of hepatology.

[49]  Y. Matsuzawa,et al.  Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. , 1999, Journal of hepatology.

[50]  G. Davis,et al.  Transforming growth factor-beta 1 in chronic hepatitis C. , 1997, Journal of viral hepatitis.